iShares Nasdaq US Biotechnology UCITS ETF

IE00BYXG2H39ETFUSDAccumulatingFigures as of October 5, 2026
See this fund's PDF factsheetFree with an account · your firm's name in the header
United States Health Care Equity
RiskHighValuationGrowthConcentrationBalancedRegionUnited StatesSectorHealth Care

iShares Nasdaq US Biotechnology UCITS ETF is a united states health care equity ETF from iShares with a total expense ratio of 0.35% and a risk indicator of 5 on the 1–7 scale. Its ten largest positions weigh 45.1% of the portfolio, which FundFacts classifies as balanced. Regional focus: United States. Sector tilt: Health Care.

Key facts

TER0.35%
Fund sizeUSD 1.3bn
InceptionOctober 19, 2017
Holdings251
Asset classEquities
BenchmarkNASDAQ Biotechnology NET Index

Risk indicator (SRRI)

1
2
3
4
5
6
7
Lower risk · lower rewardHigher risk · higher reward
Volatility 3y17.4%
Sharpe 3y0.97
Max drawdown-23.9%

Investment objective

The Share Class is a share class of a Fund which aims to achieve a return on your investment, through a combination of capital growth and income on the Fund’s assets, which reflects the return of the NASDAQ Biotechnology Index, the Fund’s benchmark index (Index).

Fund details

ISINIE00BYXG2H39
Fund houseiShares
StructureETF
Share classUSD Accumulating
Share class currencyUSD
Distribution policyAccumulating
DomicileIreland
Launch dateOctober 19, 2017
BenchmarkNASDAQ Biotechnology NET Index
ReplicationPhysical
SFDR classificationArticle 6
Asset classEquities
Fund sizeUSD 1.3bn
Number of holdings251
Equity / bond split100 / 0
Price / earnings25.3x

Fees and costs

Total expense ratio (TER)0.35%
Ongoing charges0.35%
Transaction costs0.02%
Entry charge0.00%
Exit charge0.00%
Performance fee0.00%
Reduction in yield, 1 year0.40%
Reduction in yield, holding period0.40%
Recommended holding period5 years

Growth of 100 since inception

1001502002019202120232025
Fund217NASDAQ Biotechnology NET Index220
2017-10 → 2026-10 · rebased to 100
Computed from the NAV history the issuer publishes, monthly observations, rebased to 100 at the first point.

Calendar-year returns

+25.9%2020−0.4%2021−10.5%2022+4.2%2023−1.0%2024+32.9%2025
Fund NASDAQ Biotechnology NET Index

Annualised returns

PeriodFundIndexDiff
1 Year+38.07%+38.46%−0.39%
3 Years p.a.+21.64%+21.87%−0.23%
5 Years p.a.+7.21%+7.40%−0.19%
Since Inception+8.23%+8.45%−0.22%

Largest sectors

  1. Health Care99.8%

Largest countries

  1. United States94.1%
  2. Belgium1.7%
  3. China1.1%
  4. France0.9%
  5. Germany0.8%
  6. Canada0.3%
  7. United Kingdom0.3%
  8. Denmark0.3%
  9. Netherlands0.1%
  10. Iceland0.1%

Concentration

Top 10 weight 45.1% — balanced
  1. 01GILEAD SCIENCES8.01%
  2. 02AMGEN INC7.58%
  3. 03VERTEX PHARMACEUTICALS7.48%
  4. 04MODERNA5.38%
  5. 05REGENERON PHARMACEUTICALS4.87%
  6. 06REVOLUTION MEDICINES2.95%
  7. 07ILLUMINA INC2.94%
  8. 08BIOGEN2.19%
  9. 09ALNYLAM PHARMACEUTICALS1.95%
  10. 10ROIVANT SCIENCES LTD1.71%
Full holdings (251) in the API payload.

Frequently asked questions

What is the TER of iShares Nasdaq US Biotechnology UCITS ETF?

The total expense ratio (TER) of iShares Nasdaq US Biotechnology UCITS ETF (IE00BYXG2H39) is 0.35% per year.

How risky is iShares Nasdaq US Biotechnology UCITS ETF?

iShares Nasdaq US Biotechnology UCITS ETF has a risk indicator (SRRI) of 5 on a scale from 1 (lower risk) to 7 (higher risk), which FundFacts places in the high risk band. Its 3-year volatility is 17.4%. Its maximum drawdown is -23.9%.

What are the top holdings of iShares Nasdaq US Biotechnology UCITS ETF?

The largest positions of iShares Nasdaq US Biotechnology UCITS ETF as of October 5, 2026 are GILEAD SCIENCES (8.01%), AMGEN INC (7.58%), VERTEX PHARMACEUTICALS (7.48%), MODERNA (5.38%) and REGENERON PHARMACEUTICALS (4.87%). Its ten largest holdings make up 45.1% of the portfolio, out of 251 holdings in total.

What does iShares Nasdaq US Biotechnology UCITS ETF invest in?

iShares Nasdaq US Biotechnology UCITS ETF is a united states health care equity ETF. Its largest exposures as of October 5, 2026 are by country, United States 94.1%, Belgium 1.7% and China 1.1%; by sector, Health Care 99.8%.

How has iShares Nasdaq US Biotechnology UCITS ETF performed?

iShares Nasdaq US Biotechnology UCITS ETF returned +38.07% over one year, +7.21% a year over five years and +32.9% in calendar year 2025 as of October 5, 2026, according to the NAV history iShares publishes. Past performance does not predict future returns.

Is iShares Nasdaq US Biotechnology UCITS ETF accumulating or distributing?

iShares Nasdaq US Biotechnology UCITS ETF is an accumulating share class: income from its holdings is reinvested in the fund rather than paid out.

Which index does iShares Nasdaq US Biotechnology UCITS ETF track?

iShares Nasdaq US Biotechnology UCITS ETF's benchmark is the NASDAQ Biotechnology NET Index, which it tracks using physical replication.

Where is iShares Nasdaq US Biotechnology UCITS ETF domiciled and what is its SFDR classification?

iShares Nasdaq US Biotechnology UCITS ETF is domiciled in Ireland (ISIN IE00BYXG2H39). It is classified under Article 6 of the EU Sustainable Finance Disclosure Regulation (SFDR).

Where does this data about iShares Nasdaq US Biotechnology UCITS ETF come from?

FundFacts reads it from the documents iShares publishes for this share class — product page, factsheet, key information document and, where available, holdings and NAV files — and refreshes it every 24 hours. The same factsheet is available as JSON from the FundFacts API.

Glossary

TERRisk indicator (SRRI)Max drawdownSharpe 3yReplicationSFDR classificationHow to get an ETF's holdingsHow to get a fund's TER

Download this fund as a PDF factsheet

A one-page PDF or web factsheet with the figures of this page, branded for your clients: your name in the header, your accent colour, a permanent link to share. Free with an account, ready in a minute.
Make the PDF factsheetSee this fund's PDF factsheetHow factsheets work

Get this factsheet as JSON

Everything on this page, with the largest holdings, every breakdown, the monthly series and the risk statistics, is one REST call. Any fund or ETF by ISIN, refreshed every 24 hours from the issuer's own documents.
curl https://fundfactsapi.com/api/v1/demo/funds/IE00BYXG2H39
​
# any ISIN, with a free API key
curl https://fundfactsapi.com/api/v1/funds/IE00BYXG2H39 -H "Authorization: Bearer ffk_..."
Get a free API keyField referenceCompare overlap with another fund

Ask Claude about this fund

Open a Claude conversation about iShares Nasdaq US Biotechnology UCITS ETF with this page as the source. Add the FundFacts MCP connector and Claude gets the same factsheet for every ISIN you ask about: fees, holdings, exposure, returns, overlap and portfolio look-through, with the as-of date of each figure.
Ask ClaudeConnect the MCP serverAI agents docs

More from iShares

iShares Dow Jones Global Leaders Screened UCITS ETFIE00B57X3V84 · Equities · USD
iShares Dow Jones Global Titans 50 UCITS ETF (DE)DE0006289382 · Equities · EUR
iShares Edge MSCI World Value Factor UCITS ETFIE00BP3QZB59 · Equities · USD
iShares Global Clean Energy Transition UCITS ETFIE00B1XNHC34 · Equities · USD
iShares Healthcare Innovation UCITS ETF USD (Acc)IE00BYZK4776 · Equities · USD
iShares MSCI AC Far East ex-Japan UCITS ETFIE00B0M63730 · Equities · USD
iShares MSCI All Country World UCITS ETFIE00B6R52259 · Equities · USD
iShares MSCI China Tech UCITS ETF USD (Accumulating)IE000NFR7C63 · Equities · USD
iShares MSCI EM Asia UCITS ETFIE00B5L8K969 · Equities · USD
iShares MSCI EM ex-China UCITS ETFIE00BMG6Z448 · Equities · USD
iShares MSCI EM UCITS ETF USD (Acc)IE00B4L5YC18 · Equities · USD
iShares MSCI World EUR Hedged UCITS ETF (Acc)IE00B441G979 · Equities · EUR
iShares funds & ETFs
Figures are read from the documents iShares publishes for this share class (product page, factsheet, key information document and, where available, holdings and NAV files), as of October 5, 2026. The category, risk band, concentration and tilt labels are the FundFacts profile (fundfacts-profile/3), derived from those figures with fixed, published rules. FundFacts API is independent and not affiliated with, sponsored or endorsed by iShares; fund names are used to identify the product only. Nothing on this page is investment advice.